SUBSCRIBE
SUBSCRIBE
News   Drug Development

FDA to Meet on Long-Lasting Zyprexa

January 9, 2008 | 
1 min read
WASHINGTON -The Food and Drug Administration has scheduled a meeting next month to review the safety and effectiveness of a long-acting version of Eli Lilly & Co.'s schizophrenia drug.
Clinical research Postmarket research Regulatory
Eli Lilly and Company Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Human brain with abstract visualization of neuron activity
Alzheimer’s disease
Lilly Gets FDA Label Update for Alzheimer’s Drug To Mitigate Safety Concerns
July 9, 2025
 · 
2 min read
 · 
Annalee Armstrong
Podcast
Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More
July 9, 2025
 · 
1 min read
 · 
Heather McKenzie
FDA signage at its headquarters in Maryland
ALS
ALS Community Petitions FDA To Reconsider BrainStorm’s NurOwn, Pointing to Recent Survival Data
July 8, 2025
 · 
3 min read
 · 
Heather McKenzie
Yellow Forklift truck truckraises a box over a stack of boxes and red arrow down. Decrease in economic rates, low demand for goods, decrease in import or export. Reduced storage, logistics costs
Immunology and inflammation
Jasper Crashes as Compromised Drug Lot Confounds Urticaria Study
July 8, 2025
 · 
2 min read
 · 
Tristan Manalac